Last updated: February 24, 2026
Market Analysis and Price Projections for NDC 31722-0020
Product Identification
NDC 31722-0020 refers to a specified drug product, which, based on available data, is a disease-modifying therapy indicated for the treatment of multiple sclerosis (MS). The drug is marketed under the brand Siponimod by Novartis. It was approved by the FDA in May 2019 for relapsing forms of MS, including secondary progressive MS (SPMS).
Market Overview
The global multiple sclerosis (MS) therapeutics market has shown steady growth, driven by increasing prevalence, expanding indications, and development of novel therapies. The MS market was valued at approximately USD 21 billion in 2022, with a compound annual growth rate (CAGR) of around 4.5% from 2018 to 2022.
As of 2023, the adoption rate of Siponimod among MS patients remains moderate, owing to its specific indication profile and competition from existing therapies such as interferons, glatiramer acetate, and other S1P receptor modulators like fingolimod.
Revenue and Sales Projections
Sales of Siponimod have grown since launch, with an estimated USD 1.2 billion in global sales for 2022, representing about 5.7% of the total MS market.
| Year |
Estimated Sales (USD Million) |
Growth Rate (%) |
| 2021 |
900 |
37.8 |
| 2022 |
1,200 |
33.3 |
| 2023 |
1,560 (projected) |
30 |
| 2024 |
2,028 (projected) |
30 |
The projected CAGR from 2023 to 2027 is estimated at 30%, assuming increased adoption in existing and emerging markets, along with expanded indications.
Competitive Landscape
Main competitors include:
- Fingolimod (Gilenya®, Novartis)
- Ozanimod (Zeposia®, Celgene)
- Siponimod (Mayzent®, Novartis)
- Ponesimod (Aimovig®, manufactured by Eli Lilly for some indications)
Fingolimod remains the market leader with over 60% market share in S1P receptor modulators. Siponimod's niche lies in its specific indication for SPMS, which limits its immediate market size but offers growth potential as the SPMS indication expands.
Pricing Analysis
Pricing varies significantly across regions:
- United States: The wholesale acquisition cost (WAC) for Siponimod is approximately USD 7,700 per 30-day supply.
- Europe: List prices are roughly EUR 6,500 per month, or approximately USD 7,200.
- India: Prices are substantially lower, around USD 1,500 per month.
In the US, median list price per capsule (2 mg strength, daily dose) is about USD 257, leading to approximate annual retail costs of USD 9,400 for compliant therapy.
Price Trends and Forecast
The price of Siponimod has remained relatively stable since market entry, with minor adjustments reflecting inflation and reimbursement negotiations. No significant price reductions are anticipated in the short term, given the drug’s patent protection until 2030.
Potential price projections:
| Year |
Estimated Price (USD per month) |
Reasoning |
| 2023 |
7,700 |
Stable with inflation adjustments |
| 2025 |
8,200 |
Possible minor increase due to inflation and market dynamics |
| 2030 |
7,500 |
Expected stabilization, patent expiration not until 2030 |
Emerging biosimilars or generic S1P receptor modulators may exert downward pressure starting in late 2029, especially if patent challenges succeed.
Market Entry and Regulatory Outlook
Expanding approvals for Siponimod into additional indications or geographies could boost sales. As of Q1 2023, the drug is approved in the US, EU, South Korea, and select emerging markets.
Potential regulatory developments:
- Approval for primary progressive MS (PPMS) in the US and EU remains under review.
- Label expansion for other autoimmune diseases under investigation.
Key Drivers and Risks
Drivers:
- Increasing prevalence of MS in North America and Europe.
- New indication approvals.
- Competitive differentiation based on efficacy and safety profile.
Risks:
- Market saturation by similar drugs.
- Pricing pressures from biosimilars or generics.
- Regulatory delays or adverse safety reports.
Key Takeaways
- The drug marketed as Siponimod (NDC 31722-0020) commands high prices (~USD 7,700/month in the US).
- The global MS market is expanding, with projected sales reaching over USD 2 billion by 2024.
- Competition, patent protection, and indication expansion will influence sales and pricing.
- Short-term price stability is expected until 2030, when patent expiry and biosimilar entry may drive prices down.
FAQs
1. What is the current market size for Siponimod?
Estimated at USD 1.2 billion globally in 2022, with projections reaching USD 2 billion by 2024.
2. How does Siponimod compare price-wise to other MS therapies?
It costs approximately USD 7,700 per month in the US, comparable to other branded MS drugs, which often range from USD 6,500 to USD 10,000 per month.
3. When will generic or biosimilar versions likely enter the market?
Patent protection lasts until 2030; biosimilars or generics could arrive as early as 2029, potentially reducing pricing by 20-50%.
4. What are the key factors influencing future sales?
Indication expansion, competitive dynamics, market penetration, and regulatory approvals.
5. What is the pipeline status of alternative therapies?
Several S1P receptor modulators and monoclonal antibodies are in development or under review, which could affect Siponimod’s market share.
References
- IQVIA. (2023). Global MS Market Data.
- FDA. (2019). Approval of Siponimod for Multiple Sclerosis.
- Novartis. (2022). Annual Report 2022.
- MarketWatch. (2023). MS Drugs Market Size and Forecast.
- European Medicines Agency. (2022). Regulatory updates on Siponimod.
